Next Article in Journal
Novel Insights into Guide RNA 5′-Nucleoside/Tide Binding by Human Argonaute 2
Next Article in Special Issue
Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease
Previous Article in Journal
CHMP4C Disruption Sensitizes the Human Lung Cancer Cells to Irradiation
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(1), 13;

Biobanking of Exosomes in the Era of Precision Medicine: Are We There Yet?

Department of Surgery, School of Medicine, Medical Sciences Campus, University of Puerto Rico, San Juan 00936, Puerto Rico
University of Puerto Rico Comprehensive Cancer Center, San Juan 00936, Puerto Rico
Diabetes Research Institute, University of Miami, Miami, FL 33136, USA
Facultad de Medicina, Universidad Católica de Valencia “San Vicente Mártir”, Valencia 46001, Spain
Instituto Valenciano de Patología (IVP) de la Universidad Católica de Valencia “San Vicente Mártir”, Centro de Investigación Príncipe Felipe (CIPF), Valencia 46012, Spain
Author to whom correspondence should be addressed.
Academic Editor: William Chi-shing Cho
Received: 26 November 2015 / Revised: 14 December 2015 / Accepted: 17 December 2015 / Published: 24 December 2015
(This article belongs to the Special Issue Precision Medicine—From Bench to Bedside)
Full-Text   |   PDF [773 KB, uploaded 24 December 2015]   |  


The emerge of personalized medicine demands high-quality human biospecimens with appropriate clinical annotation, especially in complex diseases such as cancer, neurodegenerative, cardiovascular, and metabolic alterations in which specimen heterogeneity and individual responses often complicate the development of precision therapeutic programs. In the growing field of extracellular vesicles (EVs) research, exosomes (EXOs)—a particular type of EVs—have been proposed as an advantageous diagnostic tool, as effective delivery vehicles and as therapeutic targets. However, the lack of consensus on isolation methods and rigorous criteria to characterize them puts the term EXO into question at the time that might explain some of the controversial results found in the literature. A lack of response in the biobank network to warrant standard optimized procedures for the isolation, characterization, and storage of EXOs will undoubtedly lead to a waste of resources and failure. This review is aimed at highlighting the increasing importance of EXOs for the clinic, especially in the cancer field, and at summarizing the initiatives taken to improve current isolation procedures, classification criteria, and storage conditions of EXOs as an effort to identify technological demands that biobank platforms face for the incorporation of EXOs and other extracellular vesicle fractions as valuable biospecimens for research. View Full-Text
Keywords: exosome; exogram; biomarker; biobank; precision medicine exosome; exogram; biomarker; biobank; precision medicine

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Mora, E.M.; Álvarez-Cubela, S.; Oltra, E. Biobanking of Exosomes in the Era of Precision Medicine: Are We There Yet? Int. J. Mol. Sci. 2016, 17, 13.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top